Vitamin D₃ enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk.

ABSTRACT:

Background

Vitamin D₃ (VitD) deficiency is linked to increased incidence and worse survival in bladder cancer (BCa). In addition to cystectomy, patients are treated with cisplatin-based chemotherapy, however 30%-50% of patients do not benefit from this treatment. The effects of VitD deficiency on response to chemotherapy remain unknown.

Methods

To test effects of VitD supplementation on the response to cisplatin we analyzed patient serum VitD levels and correlated that with survival. In vivo, VitD deficient mice were treated with cisplatin, with or without pretreatment with the active VitD metabolite, 1,25 dihydroxyvitamin D₃ (1,25D₃ ). Lastly, using BCa cell lines, T24 and RT-112, the mechanism of action of 1,25D₃ and cisplatin co

SUBMITTER: Bunch BL 

PROVIDER: S-EPMC6537042 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature